Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | LPO | P22079 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15778947 | 0.84 | TLR8 (0.37) | CHRNB2CHRNA4HTTLPOKMT2A | |
| SCHEMBL459536 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4HTTLPOKMT2A | |
| SCHEMBL317712 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNA4LPOKMT2AMEN1 | |
| SCHEMBL2513335 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL28178521 | 0.72 | CHRNB2 (0.50) | CHRNB2CHRNA4HTTLPOKMT2A | |
| Hydrochloric Acid SCHEMBL28150747 | 0.72 | CHRNB2 (0.50) | CHRNB2CHRNA4HTTLPOKMT2A | |
| SCHEMBL10739013 | 0.71 | KMT2A (0.38) | CHRNB2CHRNA4KMT2AMEN1KDM4E | |
| SCHEMBL1889711 | 0.71 | KDM4E (0.47) | KMT2AMEN1KDM4EL3MBTL1LMNA | |
| SCHEMBL16107858 | 0.70 | CHRNB2 (0.36) | CHRNB2CHRNA4LPOKMT2A | |
| SCHEMBL2722061 | 0.69 | CHRNB2 (0.56) | CHRNB2CHRNA4LPOKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560481-B2 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBVIE INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | CNR2, CNR1, TRPV1 | CHRNB2 205/4885CHRNA4 318/4885HTT 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.